Tanabe Research Labs Announce FDA Acceptance of its IND Application for TR1801-ADC (MT-8633), an ADC Targeting cMET Positive Solid Tumors

Tanabe Research Labs Announce FDA Acceptance of its IND Application for TR1801-ADC (MT-8633), an ADC Targeting cMet Positive Solid Tumors San Diego, California, February 14th, 2019: ¬†Tanabe Research Laboratories U.S.A. Inc. (TRL), a subsidiary of Mitsubishi Tanabe Pharmaceutical Corporation, is a California based research, development and clinical stage company specializing in antibody technologies to treat […]

Read More »